Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995

A W Kung; J T Ma; C Wang; K H Fu; K S Lam; R T Yeung; J Boey

doi:10.1111/j.1365-2265.1987.tb01175.x

Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995

Clin Endocrinol (Oxf). 1987 Oct;27(4):469-73. doi: 10.1111/j.1365-2265.1987.tb01175.x.

Authors

A W Kung¹, J T Ma, C Wang, K H Fu, K S Lam, R T Yeung, J Boey

Affiliation

¹ Department of Medicine, Queen Mary Hospital, University of Hong Kong.

PMID: 2893673
DOI: 10.1111/j.1365-2265.1987.tb01175.x

Abstract

Acute suppression of insulin secretion from pancreatic insulinomas by long-acting somatostatin analogue SMS 201-995 has been documented. We report the chronic use of the drug in a patient with persistent hypoglycaemia due to benign pancreatic microadenomatosis with satisfactory control of plasma glucose level and reduction of insulin production. There was no tachyphylaxis or untoward side-effect noted during the 6-month treatment period.

Publication types

Case Reports

MeSH terms

Adenoma / complications*
Adenoma / metabolism
Adenoma / surgery
Female
Humans
Hypoglycemia / drug therapy*
Hypoglycemia / etiology
Insulin / metabolism
Insulin Secretion
Middle Aged
Octreotide
Pancreatectomy
Pancreatic Neoplasms / complications*
Pancreatic Neoplasms / metabolism
Pancreatic Neoplasms / surgery
Somatostatin / analogs & derivatives*
Somatostatin / therapeutic use

Substances

Insulin
Somatostatin
Octreotide